FAS and hepatocellular carcinoma: Significantly lower expression of IL-35 was also observed in Hepatocellular carcinoma patients. IL-35 over-expression in HepG2 cells significantly upregulated HLA-ABC and CD95, reduced activities of MMP-2 and MMP- 9, and decreased cell migration, invasion and colony formation capacities